Jürgen Curschmann

TL;DR: The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.

TL;DR: The assessment of the precise tumor extent of recurrent glottic carcinomas is a challenge and the need for further research is to be determined.

TL;DR: Chondroradionecrosis is a relatively rare treatment complication that may be present beneath an intact mucosa and missed by endoscopy and typical imaging findings suggestive of radionicrosis are often missing.

TL;DR: MS provides excellent efficacy and morbidity results in groups I and II meningiomas, especially in asymptomatic patients and might therefore be considered the first choice of treatment for these patients.

TL;DR: Approximately 50% of patients with astrocytic WHO grade II gliomas respond to RT despite the absence of LOH for 1p/19q, and the potential predictive factors for response and the impact of response on overall survival remain unclear.